Physician profile
John D Zarick
NPI 1275187452
$611.80
in general payments reported to CMS, 2019-2025
12 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.16 · 2024: $133 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $488.19 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $160.77 | 2025 | Austedo Xr |
| Abbvie INC. | $101.68 | 2024-2025 | |
| Pfizer INC. | $66.14 | 2025 | |
| Sk Life Science, INC. | $49.54 | 2024-2025 | |
| Emd Serono, INC. | $48.33 | 2024-2025 | |
| Lundbeck LLC | $46.10 | 2024-2025 | Vyepti |
| Acadia Pharmaceuticals INC | $42.18 | 2024-2025 | Nuplazid |
| Janssen Biotech, INC. | $35.90 | 2025 | |
| Neurocrine Biosciences, INC. | $17.48 | 2025 | |
| Aucta Pharmaceuticals, INC. | $16.76 | 2025 | Motpoly Xr |
| Cycle Pharmaceuticals INC | $14.76 | 2024 | Tascenso Odt |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Zarick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.